Sands BE - Search Results

1

When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations.

Siegel CA, Schwartz LM, Woloshin S, Cole EB, Rubin DT, Vay T, Baars J, Sands BE. Siegel CA, et al. Among authors: sands be. Inflamm Bowel Dis. 2010 Oct;16(10):1658-62. doi: 10.1002/ibd.21233. Inflamm Bowel Dis. 2010. PMID: 20186940 Free PMC article.

2

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Sands BE, et al. Inflamm Bowel Dis. 2001 May;7(2):83-8. doi: 10.1097/00054725-200105000-00001. Inflamm Bowel Dis. 2001. PMID: 11383595 Clinical Trial.

3

A survey of methodological variation in the Crohn's disease activity index.

Sands BE, Ooi CJ. Sands BE, et al. Inflamm Bowel Dis. 2005 Feb;11(2):133-8. doi: 10.1097/00054725-200502000-00006. Inflamm Bowel Dis. 2005. PMID: 15677906

4

Review article: practical management of inflammatory bowel disease patients taking immunomodulators.

Siegel CA, Sands BE. Siegel CA, et al. Among authors: sands be. Aliment Pharmacol Ther. 2005 Jul 1;22(1):1-16. doi: 10.1111/j.1365-2036.2005.02520.x. Aliment Pharmacol Ther. 2005. PMID: 15963074 Free article. Review.

5

Risk factors for colorectal cancer in Crohn's colitis: a case-control study.

Siegel CA, Sands BE. Siegel CA, et al. Among authors: sands be. Inflamm Bowel Dis. 2006 Jun;12(6):491-6. doi: 10.1097/00054725-200606000-00008. Inflamm Bowel Dis. 2006. PMID: 16775493

6

Risks and benefits of infliximab for the treatment of Crohn's disease.

Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Siegel CA, et al. Among authors: sands be. Clin Gastroenterol Hepatol. 2006 Aug;4(8):1017-24; quiz 976. doi: 10.1016/j.cgh.2006.05.020. Epub 2006 Jul 14. Clin Gastroenterol Hepatol. 2006. PMID: 16843733

7

Possible association between isotretinoin and inflammatory bowel disease.

Reddy D, Siegel CA, Sands BE, Kane S. Reddy D, et al. Among authors: sands be. Am J Gastroenterol. 2006 Jul;101(7):1569-73. doi: 10.1111/j.1572-0241.2006.00632.x. Am J Gastroenterol. 2006. PMID: 16863562

8

Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy.

Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, Sands BE. Johnson FR, et al. Among authors: sands be. Gastroenterology. 2007 Sep;133(3):769-79. doi: 10.1053/j.gastro.2007.04.075. Epub 2007 May 3. Gastroenterology. 2007. PMID: 17628557

9

Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease.

Siegel CA, Levy LC, Mackenzie TA, Sands BE. Siegel CA, et al. Among authors: sands be. Inflamm Bowel Dis. 2008 Jan;14(1):1-6. doi: 10.1002/ibd.20283. Inflamm Bowel Dis. 2008. PMID: 17924559

10

Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis.

Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE. Kaplan GG, et al. Among authors: sands be. Gastroenterology. 2008 Mar;134(3):680-7. doi: 10.1053/j.gastro.2008.01.004. Epub 2008 Jan 10. Gastroenterology. 2008. PMID: 18242604

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

376 results

Search Page

Filters